A prospective randomised controlled trial assessing the efficacy of Pegatanib sodium (Macugen®) in the prevention of proliferative diabetic retinopathy
Phase 4
Completed
- Conditions
- Topic: EyeSubtopic: Eye (all Subtopics)Disease: OphthalmologyEye DiseasesProliferative diabetic retinopathy
- Registration Number
- ISRCTN27864936
- Lead Sponsor
- Frimley Park Hospital NHS Foundation Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
Not provided at time of registration
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Pegatanib sodium target in proliferative diabetic retinopathy?
How does Pegatanib sodium compare to anti-VEGF therapies in preventing retinal neovascularization?
Are there specific biomarkers that predict response to Pegatanib sodium in diabetic retinopathy patients?
What adverse events are associated with Pegatanib sodium in ophthalmic clinical trials?
What are the potential combination therapies involving Pegatanib sodium for eye disease management?